Patents Assigned to Biogen MA Inc.
  • Biaryl bruton's tyrosine kinase inhibitors
    Patent number: 10280169
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: May 7, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Gnanasambandam Kumaravel, Hua Miao, Andrea Bertolotti-Ciarlet, Kevin Otipoby
  • Methods of Treating Multiple Sclerosis
    Publication number: 20190125710
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 2, 2019
    Applicant: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Compounds that are S1P modulating agents and/or ATX modulating agents
    Patent number: 10273234
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: April 30, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Lihong Sun, Zhili Xin, Lei Zhang
  • IRAK4 inhibiting agents
    Patent number: 10246456
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: April 2, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffery Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield
  • Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate
    Publication number: 20190091146
    Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Applicant: Biogen MA Inc.
    Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
  • PHARMACEUTICAL MATRIX FORMULATIONS COMPRISING DIMETHYL FUMARATE
    Publication number: 20190083404
    Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a tablet and comprise one or more extended release polymer matrix. Also provided are pharmaceutical compositions in the form of a capsule comprising one or more tablets of the present invention. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 21, 2019
    Applicants: BIOGEN MA INC., BIOGEN MA INC.
    Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Yiqing Lin
  • CONTROL OF PROTEIN GLYCOSYLATION BY CULTURE MEDIUM SUPPLEMENTATION AND CELL CULTURE PROCESS PARAMETERS
    Publication number: 20190085369
    Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.
    Type: Application
    Filed: April 16, 2018
    Publication date: March 21, 2019
    Applicants: Biogen MA Inc., Samsung Bioepis
    Inventors: William C. Yang, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Liu Tsang, Thomas Ryll, Sangil Lee, Dae Sung Lee
  • Methods of treating inflammatory and autoimmune diseases with natalizumab
    Patent number: 10233245
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: March 19, 2019
    Assignee: BIOGEN MA INC.
    Inventor: Ivan Lieberburg
  • Inhibiting agents for bruton's tyrosine kinase
    Patent number: 10227341
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: March 12, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos
  • Method for delivering interferon-beta
    Patent number: 10220074
    Abstract: The method described herein reduces the amount of aggregating metal released into solutions of Interferon-.beta.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: March 5, 2019
    Assignee: Biogen MA Inc.
    Inventors: Eric Anthony Faulkner, Mary Diana DiBiase
  • USE OF LINGO-4 ANTAGONISTS IN THE TREATMENT OF CONDITIONS INVOLVING DEMYELINATION
    Publication number: 20190060398
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 28, 2019
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, John McCoy
  • FORMULATIONS AND SCREENING OF BIOLOGICAL THERAPEUTIC AGENTS
    Publication number: 20190064147
    Abstract: Provided herein, in some aspects, are methods of developing a biological therapeutic product. The methods can be used to formulate a biological therapeutic agent or screen biological therapeutic agents.
    Type: Application
    Filed: January 18, 2016
    Publication date: February 28, 2019
    Applicant: Biogen MA Inc.
    Inventors: Mark Krebs, Mariana Dimitrova, Kapil Gupta, Shantanu Sule, Randall Mauldin, Adnan Zunic, Lori Karpes
  • Wearable medical detector
    Patent number: 10206639
    Abstract: Various embodiments of medical detector systems as well as their methods of operation are disclosed. In one embodiment, one or more detectors are coupled to wearable structures for detecting at least a first tracer within a body portion. In another embodiment, one or more detectors are coupled to a wearable structure, where the detector corresponds to a CMOS chip that directly detects a first radioactive tracer.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: February 19, 2019
    Assignee: Biogen MA Inc.
    Inventors: Ajay Verma, Marisa J. Bober, Victoria Cabot, Courtney D. Hilliard, Ara N. Knaian, Seth O. Newburg, John William Hoppin, Karl F. Schmidt
  • BISPECIFIC ANTIBODY PLATFORM
    Publication number: 20190048098
    Abstract: Provided herein are solutions to the heavy and light chain mispairing problems in bispecific antibodies. One part of the solution involves Fc regions that are engineered in their CH3 domains by lysine repositioning to drive heterodimerization of the two heavy chains of the bispecific antibody. The second part of the solution involves a modification of one of the two Fab arms of the bispecific antibody so as to prevent mispairing of light chains in the bispecific antibody. Specifically, the CH1 and CL domains of one of the Fab arms of the bispecific antibody are substituted with an IgE CH2 domain or an IgM CH2 domain.
    Type: Application
    Filed: December 15, 2016
    Publication date: February 14, 2019
    Applicant: Biogen MA Inc.
    Inventor: Martin Preyer
  • PHARMACEUTICAL BEAD FORMULATIONS COMPRISING DIMETHYL FUMARATE
    Publication number: 20190046456
    Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
    Type: Application
    Filed: February 8, 2017
    Publication date: February 14, 2019
    Applicant: BIOGEN MA INC.
    Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
  • Combination Therapies and Uses for Treatment of Demyelinating Disorders
    Publication number: 20190038744
    Abstract: Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.
    Type: Application
    Filed: February 20, 2018
    Publication date: February 7, 2019
    Applicant: Biogen MA Inc.
    Inventors: Diego Cadavid, Sha Mi
  • COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
    Publication number: 20190040384
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: February 28, 2018
    Publication date: February 7, 2019
    Applicant: Biogen MA Inc.
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo
  • COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
    Publication number: 20190030058
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: February 9, 2018
    Publication date: January 31, 2019
    Applicants: Biogen MA Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
  • Inhibiting agents for Bruton's tyrosine kinase
    Patent number: 10189829
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 29, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 10189817
    Abstract: The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: January 29, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Xiongwei Cai, Timothy R. Chan, Patrick Conlon, Michael Humora, Tracy J. Jenkins, J. Michael Macphee, Xianglin Shi, Ross A. Miller, Andrew Thompson